Viridian Therapeutics Q2 2024 Adj EPS $(1.02) Misses $(0.89) Estimate, Sales $72.00K Miss $86.15K Estimate
Portfolio Pulse from Benzinga Newsdesk
Viridian Therapeutics (NASDAQ: VRDN) reported Q2 2024 adjusted EPS of $(1.02), missing the analyst estimate of $(0.89) by 14.61%. The company also reported sales of $72.00K, missing the estimate of $86.15K by 16.43%.
August 08, 2024 | 12:29 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Viridian Therapeutics reported a significant miss on both EPS and sales for Q2 2024, which is likely to negatively impact the stock price in the short term.
The company's EPS missed the consensus estimate by 14.61% and sales missed by 16.43%. Such significant misses typically result in a negative market reaction, leading to a short-term decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100